Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis

由 Schmid, Ulrike, Liesenfeld, Karl-Heinz, Fleury, Angele, Dallinger, Claudia, Freiwald, Matthias
發表在 Cancer Chemother Pharmacol (2017)

Pharmacometric Characterization of Dabigatran Hemodialysis

由 Liesenfeld, Karl-Heinz, Staab, Alexander, Härtter, Sebastian, Formella, Stephan, Clemens, Andreas, Lehr, Thorsten
出版 2013

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic simi...

由 Kang, Jia, Eudy‐Byrne, Rena J., Mondick, John, Knebel, William, Jayadeva, Girish, Liesenfeld, Karl‐Heinz
發表在 Br J Clin Pharmacol (2020)

Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis

由 Liesenfeld, Karl-Heinz, Schäfer, Hans G, Trocóniz, Iñaki F, Tillmann, Christiane, Eriksson, Bengt I, Stangier, Joachim
出版 2006

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled...

由 Moschetti, Viktoria, Desch, Michael, Goetz, Sophia, Liesenfeld, Karl-Heinz, Rosenbrock, Holger, Kammerer, Klaus-Peter, Wunderlich, Glen, Wind, Sven
發表在 Eur J Drug Metab Pharmacokinet (2017)

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokine...

由 Moschetti, Viktoria, Schlecker, Christina, Wind, Sven, Goetz, Sophia, Schmitt, Holger, Schultz, Armin, Liesenfeld, Karl-Heinz, Wunderlich, Glen, Desch, Michael
發表在 Clin Drug Investig (2018)

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

由 Johnston, Curtis K., Eudy-Byrne, Rena J., Elmokadem, Ahmed, Nock, Valerie, Marquard, Jan, Soleymanlou, Nima, Riggs, Matthew M., Liesenfeld, Karl-Heinz
發表在 Pharmaceutics (2021)

Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder

由 Tsuda, Yasuhiro, Tatami, Shinji, Yamamura, Norio, Tadayasu, Yusuke, Sarashina, Akiko, Liesenfeld, Karl-Heinz, Staab, Alexander, Schäfer, Hans-Günter, Ieiri, Ichiro, Higuchi, Shun
出版 2010

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

由 Rosenbrock, Holger, Desch, Michael, Kleiner, Oliver, Dorner‐Ciossek, Cornelia, Schmid, Bernhard, Keller, Sascha, Schlecker, Christina, Moschetti, Viktoria, Goetz, Sophia, Liesenfeld, Karl‐Heinz, Fillon, Gwenaelle, Giovannini, Riccardo, Ramael, Steven, Wunderlich, Glen, Wind, Sven
發表在 Clin Transl Sci (2018)

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

由 Perkins, Bruce A., Soleymanlou, Nima, Rosenstock, Julio, Skyler, Jay S., Laffel, Lori M., Liesenfeld, Karl‐Heinz, Neubacher, Dietmar, Riggs, Matthew M., Johnston, Curtis K., Eudy‐Byrne, Rena J., Elmokadem, Ahmed, George, Jyothis T., Marquard, Jan, Nock, Valerie
發表在 Diabetes Obes Metab (2020)